

PERSONAL INFORMATIONS **Salvatore Corallo**

✉ Salvatore.corallo@universitadipavia.it

Scopus Author ID: 57193265787

ORCID ID: 0000-0002-6672-0233

Date of Birth: 03/09/1986

Nationality Italian

Current Position: Researcher (RTDB) at University of Pavia and Medical Oncologist at IRCCS Policlinico San Matteo, Pavia

PROFESSIONAL EXPERIENCES

- From 15th July 2024 to present: researcher (RTDB) at University of Pavia (Corso Alberto 5, 27100 Pavia) and Medical Oncologist at IRCCS Policlinico San Matteo
- From 1st October 2021 to 14th July 2024: Medical Oncologist resident at Fondazione IRCCS Policlinico San Matteo, Oncology department Viale C. Golgi 19, Pavia.
- From 16th April 2021 to 30th September 2021: Medical Oncologist resident at Fondazione IRCCS Istituto Nazionale dei Tumori, division of Gastrointestinal Oncology Via G. Venezian 1, Milan
- From 01st August 2017 to 15th April 2021 attendance as Medical Oncologist at Fondazione IRCCS Istituto Nazionale dei Tumori, division of Gastrointestinal Oncology Via G. Venezian 1, Milan
- From July 2012 to July 2017 medical oncology fellowship at Università Cattolica del Sacro Cuore, Policlinico Agostino Gemelli, Largo F. Vito 1, Rome.
- From October 2011 to July 2012 voluntary attendance in: Medical Oncology Department of Policlinico A. Gemelli, Largo F. Vito 1, in Rome

OTHER PROFESSIONAL EXPERIENCES

- From October 2021, currently ongoing: tutor for Residents in Medical oncology in the Pavia University.
- From October 2021, currently ongoing: Tutor for medicine students of traditional program and Harvey Course in the University of Pavia.

INSTRUCTION AND FORMATION

- 03rd July 2017: Specialization in Medical Oncology (50/50 cum laude) Università Cattolica del Sacro Cuore; Largo F. Vito 1, Rome. Thesis title: The effect of the evaluation in a multidisciplinary team (mdt) setting on outcome following hepatic resection for colorectal liver metastases
- 18th October 2011: Full cycle degree in Medicine and Surgery (110/100 cum laude) Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome. Thesis title: Impatto del programma di “palliative simultaneous care” sull’esito complessivo dei pazienti oncologici
- 2005: High school diploma (mark: 100/100) Liceo Classico “Gaetano Curcio”, Via Andreoli 2, Ispica (Ragusa)

PERSONAL SKILLS

Language Italian

Other Languages

	COMPREHENSION		SPEAKING		WRITING
	Listening	Reading	Interaction	Oral Production	
ENGLISH	B1	B1	B1	B1	B2

(*)Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user

[Common European Framework of Reference for Languages](#)

Digital Skills

- Excellent command of the office suite tools (word processor, spreadsheet, presentation software).
- Excellent command of Excel.

Additional Skills

- September 2004: Lower completion of piano, Conservatorio “Vincenzo Bellini”, Caltanissetta

EXPERIENCES IN CLINICAL TRIALS

- ICH Good Clinical Practice E6 (R2)
 - From August 2012 co-investigator or primary investigators in sponsored and academic Clinical Trials mainly focused on gastrointestinal cancers.
-

PROFESSIONAL SOCIETIES

- ESMO: European Society of Medical Oncology
 - AIOM: Associazione Italiana di Oncologia Medica
-

AWARDS

- 18th October 2019: First position at the V edition Premio Marzia Galli Kienle 2019
 - 16th October 2005: “Alfiere del Lavoro” Medal of the Italia Republic President
 - 28th May 2005: winner of the literary prize “la vita oltre la morte” –prose section
 - 23rd June 2004: Winner of the literary prize “Cunti della contea di Modica” edition 2004
-

ORAL PRESENTATION AS FIRST AUTHOR

- AIOM 2018 Annual Meeting: “Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus Pan or single-agent Pan: translational analyses of the VALENTINO study”.
-

CONGRESS AS RELATOR

Title: Convegno nazionale AIOM giovani 2017

Location: Perugia

Organizer: AIOM

From 07/07/2017 to 08/07/2017

Contributed as: invited speaker

Title: Il valore del tempo in oncologia: nuove opzioni nel trattamento del tumore coloretale metastatico nelle linee avanzate

Location: Milan

Organizer: Ospedale Niguarda Ca' Granda

From 25/09/2018 to 25/09/2018

Contributed as: invited speaker

Title: terapie di supporto in oncologia: strategia "sistemica" al servizio del paziente -2°
edizione

Location: Milan

Organizer: Fondazione IRCCS Istituto Nazionale dei Tumori - Milan

From 05/10/2018 to 05/10/2018

Contributed as: invited speaker

Title: News in oncology: focus on gastrointestinal tumors

Location: Milan

Organizer: Fondazione IRCCS Istituto Nazionale dei Tumori - Milan

From 26/10/2018 to 26/10/2018

Contributed as: invited speaker

Title: corso di immunoterapia in oncologia 2018

Location: Bari

Organizer: AIOM

From 08/11/2018 to 09/11/2018

Contributed as: invited speaker

Title: Tumori del tratto gastroenterico: stato dell'arte e nuovi orizzonti

Location: Catania

Organizer: Istituto Oncologico del Mediterraneo

From 22/02/2019 to 23/02/2019

Contributed as: invited speaker

Title: Gastro Journal: l'importanza della ricerca in Oncologia

Location: Rome

Organizer: Over Group

From 10/10/2019 to 11/10/2019

Contributed as: invited speaker

Title: Il edition news in oncology: focus on gastrointestinal tumors

Location: Milan

Organizer: Fondazione IRCCS Istituto Nazionale dei tumori di Milano

From 31/01/2020 to 31/01/2020

Contributed as: invited speaker

Title: VI corso annual tumori gastrointestinali: dalla pratica clinica alla biologia –Updates in research and practice in GI cancer

Location: FAD

Organizer: MI and t SRL

From 20/10/2020 to 20/10/2020

Contributed as: invited speaker

Title: XXII Congresso Nazionale AIOM 2020- Ricerca, accessibilità e organizzazione

Location: FAD

Organizer: AIOM

From 31/10/2020 to 02/11/2020

Contributed as: invited speaker

Title: Back from ASCO and ESMO GI word Congress 2021

Location: FAD

Organizer: A and Q

From 09/07/2021 to 09/07/2021

Contributed as: invited speaker

Title: Young news form Barcellona. First Edition

Location: FAD

Organizer: Motus Animi

From 07/07/2022 to 07/07/2022

Contributed as: invited speaker

Title: Neoplasie dello stomaco e del colon: le opzioni terapeutiche nelle linee avanzate

Location: Pavia

Organizer: Accademia Nazionale di Medicina

From 21/10/2022 to 21/10/2022

Contributed as: invited speaker

Title: MASTERCLASS mCRC: from clinical practice to storytelling- part 1

Location: Milan

Organizer: Qb group

From 17/05/2023 to 17/05/2023

Contributed as: invited speaker

Title: I tumori del pancreas: dalla diagnosi alla terapia

Location: Pavia

Organizer: Studio Congressi

From 19/05/2023 to 19/05/2023

Contributed as: invited speaker

Title: MASTERCLASS mCRC: from clinical practice to storytelling- part 2

Location: Milan

Organizer: Qb group

From 13/09/2023 to 13/09/2023

Contributed as: invited speaker

Title: Carcinoma epatocellulare: nuove evidenze cliniche e aspetti gestionali

Location: FAD

Organizer: Accademia Nazionale di Medicina

From 16/11/2023 to 16/11/2023

Contributed as: invited speaker

Title: Masterclass NextGen

Location: Reggio Emilia

Organizer: qbgroup

From 16/05/2024 to 17/05/2024

Contributed as: invited speaker

PUBLICATIONS

- Maestri M, Cicerone O, Messina A, Gallotti A, Corallo S, Mauramati S, Canzi P,

Fiandrino G, Paulli M, Vanoli A. Pink-on-pink: hepatocellular carcinoma metastatic to oncocytic carcinoma of the thyroid. *Pathologica* 2024;116:158-162;doi: 10.32074/1591-951X-922

-

- Aquilani R, Brugnattelli S, Maestri R, Iadarola P, Corallo S, Pagani A, Serra F, Bellini A, Buonocore D, Dossena M, Boschi F and Verri M. (2024) **Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.** *Int. J. Mol. Sci.* 25, 5300. <https://doi.org/10.3390/ijms25105300>

-

- Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini Casadei A, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset Droz Ditac M, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro, V. (2024) **A phase II/III randomized clinical trial of CisPlatin plus Gemcitabine and Nabpaclitaxel (GAP) as preoperative chemotherapy versus immediate resection in patients with resectable Biliary Tract Cancers (BTC) at high risk for recurrence: PURITY study.** *BMC Cancer*, 24(1), 436

-

- Speranza D, Sapuppo E, Aprile G, Auriemma A, Bergamo F, Bianco R, Bordonaro R, Brandi Giovanni, Brunetti O, Carnaghi C, Ciliberto D, Cinieri S, Corallo S, De Vita F, Di Donato S, Ferrà F, Fornaro L, Barucca V, Giommoni E, Lotesoriere C, Luchini C, Masini C, Niger M, Pisconti S, Rapposelli IG, Rimassa L, Rognone C, Rodriquenz MG, Corsini LR, Santin D, Scarpa A, Scartozzi M, Soto Parra H, Tonini G, Tortora G, Tralongo P, Silvestris N. (2024) **The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell'Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO).** *Tumori.* 7:3008916231222761. doi: 10.1177/03008916231222761

-

- Casirati A, Da Prat V, Cereda E, Serra F, Perrone L, Corallo S, De Lorenzo F, Pedrazzoli P, Caccialanza R (2023). **The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition.** *NUTRIENTS*, vol. 15, ISSN: 2072-6643, doi: 10.3390/nu15010235

-

- Faris P, Rumolo A, Pellavio G, Tanzi M, Vismara M, Berra-Romani R, Gerbino A, Corallo S, Pedrazzoli P, Laforenza U, Montagna D, Moccia F (2023). **Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca²⁺ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells.** *CELL DEATH DISCOVERY*, vol. 9, ISSN: 2058-7716, doi: 10.1038/s41420-023-01530-x

-

- Fugazzola P, Moroni A, Agnoletti V, Catena F, Cobiانchi L, Corallo S, Dal Mas F, Frassini S, Maestri M, Magnone S, Pagani A, Pedrazzoli P, Rigamonti A, Santandrea G, Tomasoni M, Vallicelli C, Viganò J, Ansaloni L (2023). **Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS plus HIPEC?** *UPDATES IN SURGERY*, ISSN: 2038-131X, doi: 10.1007/s13304-023-01579-4 EA JUL 2023

-

- Serra F, Pedrazzoli P, Brugnattelli S, Pagani A, Corallo S, Rosti G, Caccialanza R, Viganò J, Carminati O. **Nutritional support management in resectable gastric cancer** *Drugs Context.*

2022 doi: 10.7573/dic.2022-5-1.

-

- Prisciandaro M, Antista M, Raimondi A, Corti F, Morano F, Centonze G, Sabella G, Mangogna A, Randon G, Pagani F, Prinzi N, Niger M, Corallo S, di Caronno EC, Massafra M, Di Bartolomeo M, de Braud F, Milione M, Pusceddu S **Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.** FRONTIERS IN ONCOLOGY, 2022 vol. 12, 780716, ISSN: 2234-943X, doi: 10.3389/fonc.2022.780716

-

- Fuca G, Raimondi A, Prisciandaro M, Lonardi S, Cremolini C, Ratti M, Clavarezza M, Murialdo R, Sartore-Bianchi A, Smiroldo V, Berenato R, Racca P, Bergamo F, Corallo S, Di Bartolomeo M, De Braud F, Morano F, Pietrantonio F. **Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.** THE ONCOLOGIST (2022), vol. 27, p. E29-E36, ISSN: 1083-7159, doi: 10.1093/oncolo/oyab012

-

- Manca P, Corallo S, Lonardi S, Fuca G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, Pietrantonio F. **Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.** BRITISH JOURNAL OF CANCER, 2021, vol. 126, p. 449-455, ISSN: 0007-0920, doi: 10.1038/s41416-021-01591-8 EA NOV 2021

-

- Lonardi S, Prete AA, Morano F, Messina M, Formica V, Corsi DC, Orciuolo C, Frassinetti GL, Zampino MG, Casagrande M, Masi G, Ronzoni M, Scartozzi M, Buonadonna A, Mosconi S, Ratti M, Sartore-Bianchi A, Tamburini E, Prisciandaro M, Bergamo F, Spada M, Corallo S, Vettore V, Loupakis F, Fassan M, Del Bianco P, Zagonel V, Pietrantonio F (2021). **Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.** JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 9, ISSN: 2051-1426, doi: 10.1136/jitc-2021-002996

-

- Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V, Amatu A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti R, Corallo S, Morano F, Di Bartolomeo M, Di Maio M, Pietrantonio F. **Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study.** ESMO Open, 6 (5) 2021. doi.org/10.1016/j.esmoop.2021.100246

-

- Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, Curigliano G, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. **The prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors** J Immunother Cancer. 2021; 9(4):e002501. doi: 10.1136/jitc-2021-002501

-

- Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli Romario U, de Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, de Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB; Giordano S. **Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas.** *Clinical Cancer Res* 2021 doi: 10.1158/1078-0432.CCR-20-0121
-
- Manca P, Corallo S, Busico A, Lonardi S, Corti F, Antoniotti C, Procaccio L, Clavarezza M, Smiroldo V, Tomasello G, Murialdo R, Sartore-Bianchi A, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Palermo F, Perrone F, Tamborini E, Prisciandaro M, Raimondi A, Di Bartolomeo M, Morano F, Pietrantonio F. **The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer** *Clinical Cancer Res* 2021
-
- Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. **Systemic doxycycline for pre-emptive treatment of anti-EGFR related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post-hoc analysis of the Valentino.** *Support Care Cancer* 2021; doi: 10.1007/s00520-020-05972-2. Online ahead of print.
-
- Pietrantonio F, Fucà G, Rossini D, Schmoll HJ, Bendell JC, Morano F, Antoniotti C, Corallo S, Borelli B, Raimondi A, Marmorino F, Niger M, Boccaccino A, Masi G, Lonardi S, Boni L, de Braud F, Di Bartolomeo M, Falcone A, Cremolini C. **FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis.** *Oncologist.* 2020. doi: 10.1002/onco.13642.
-
- Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smiroldo V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F; Calareso G, Morano F, Pietrantonio F. **Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.** *European Journal of Cancer* 2020; 144:31-40. doi: 10.1016/j.ejca.2020.11.017.) 31e40.
-
- Antoniotti C, Borelli B, Rossini D, Pietrantonio F, Morano F, Salvatore L, Lonardi S, Marmorino F, Tamperi S, Corallo S, Tortora G, Bergamo F, Di Stefano B, Boccaccino A, Grassi E, Racca P, Tamburini E, Aprile G, Moretto R, Boni L, Falcone A and Cremolini C. **AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.** *BMC Cancer*, 2020, 683. doi.org/10.1186/s12885-020-07169-6.
-
- Basso M, Corallo S, Calegari MA, Zurlo V, Ardito F, Vellone M, Marchesani S, Orlandi

A, Dadduzio V, Di Dio C, Mele C, Barbaro B, Strippoli A, Coppola A, Cassano A, Bria E, Barone CA, Giulianti F **The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases.** Scientific Report 2020. doi: 10.1038/s41598-020-67676-1.

-

- Moretto R, Corallo S, Belfiore A, Rossini D, Boccaccino A, Lonardi S, Centonze G, Morano F, Germani MM, Loupakis F, Morelli L, Urbani L, Brich S, Marmorino F, Prisciandaro M, Aprile G, Fassan M, Cillo U, Cattaneo L, Fontanini G, De Braud F, Falcone A, Milione M, Pietrantonio F, Cremolini C. **Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: a pooled analysis of five prospective trial.** European Journal of Cancer. Eur J Cancer, 2020; 78-88. doi: 10.1016/j.ejca.2020.04.045. Epub 2020 Jun 15

-

- Raimondi A, Di Maio M, Morano F, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Sartore-Bianchi A, Tampellini M, Ritorto G, Murialdo R, Clavarezza M, Zaniboni A, Adamo V, Tomasello G, Petrelli F, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Bergamo F, Niger M, Antista M, Peverelli G, De Braud F, Di Bartolomeo M, Pietrantonio F. **Health-related Quality of Life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab-based first-line treatment strategy.** European Journal of Cancer, 2020; :230-239.

-

- Di Bartolomeo M, Raimondi A, Cecchi F, Catenacci DVT, Schwartz S, Sellappan S, Tian Y, Miceli R, Pellegrinelli A, Giommoni E, Aitini E, Spada F, Rosati G, Marchet A, Pucci F, Zaniboni A, Tamberi S, Pressiani T, Sanna G, Cantore M, Mosconi S, Bolzoni P, Pinto C, Landi L, Soto Parra HJ, Cavanna L, Corallo S, Martinetti A, Hembrough TA and Pietrantonio F. **Association of high TUBB3 with resistance to adjuvant docetaxelbased chemotherapy in gastric cancer: translational study of ITACA-S** Tumori Journal 2021;107(2):150-159

-

- Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, De Braud F, Di Bartolomeo M. **Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan** Clinical Colorectal Cancer 2020. <https://doi.org/10.1016/j.clcc.2020.05.004>

-

- Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. **Efficacy and safety of immune checkpoint inhibitors in patients with MSI-high end-stage cancers and poor performance status related to high disease burden.** Oncologist. 2020. doi: 10.1634/theoncologist.2020-0014

-

- Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Clavarezza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. **The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.** Br J Cancer 2020, 123(3):403-409. doi:

10.1038/s41416-020-0894-7.

-
- Chen C, Di Bartolomeo M, Corallo S, Strickler JH, Goyal L. **Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come** Am Soc Clin Oncol Educ Book 2020 May;40:161-173. doi: 10.1200/EDBK_280871.
-
- Corallo S, Fucà G, Morano F, Salati M, Spallanzani A, Gloghini A, Volpi CC, Trupia DV, Lobefaro R, Guarini V, Milione M, Cattaneo L, Antista M, Prisciandaro M, Raimondi A, Sposito C, Mazzaferro V, de Braud F, Pietrantonio F, Di Bartolomeo M. **Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials.** Oncologist. 2020 Apr 9. doi: 10.1634/theoncologist.2020-0037.
-
- Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A. **Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.** Lancet Oncology 2020; DOI:[https://doi.org/10.1016/S1470-2045\(19\)30862-9](https://doi.org/10.1016/S1470-2045(19)30862-9)
-
- Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F, ITACA-S study group. **Prognostic and predictive value of microsatellite instability, inflammatory reaction and PD-L1 in gastric cancer patients treated with either adjuvant 5-FU/LV or sequential FOLFIRI followed by cisplatin and docetaxel. A translational analysis from the ITACA-S Trial.** Oncologist. 2019 Nov 25. t.2019-0471. doi: 10.1634/theoncologist.2019-0471
-
- Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. **Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial** JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6486
-
- Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F **Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer.** Clin Cancer Res. 2019. doi: 10.1158/1078-0432.CCR-19-3024
-
- Morano F, Corallo S, Lonardi S, Raimondi A; Cremolini C, Rimassa L, Murialdo R,

Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F. **Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.** *J Clin Oncol.* 2019 Sep 20;JCO1901254. doi: 10.1200/JCO.19.01254.

-
- Petrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. **Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.** *JAMA Oncol.* 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467.

-
- Di Bartolomeo M, Niger M, Morano F, Corallo S, Antista M, Tamperi S, Lonardi S, Di Donato S, Berardi R, Scartozzi M, Cardellino GG, Di Costanzo F, Rimassa L, Luporini AG, Longarini R, Zaniboni A, Bertolini A, Tomasello G, Pinotti G, Scagliotti G, Tortora G, Bonetti A, Spallanzani A, Frassinetti GL, Tassinari D, Giuliani F, Cinieri F, Maiello E, Verusio C, Bracarda S, Catalano V, Basso M, Ciuffreda L, De Vita F, Soto Parra H, Fornaro L, Caporale M, de Braud F and Pietrantonio F. **Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.** *BMC Cancer* (2019) 19:283

-
- Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, de Braud F, Pietrantonio F. **Metronomic capecitabine plus cyclophosphamide regimen in unresectable or relapsed Pseudomyxoma Peritonei** *Clinical Colorectal Cancer* 2019

-
- Schirripa M, Biason P, Lonardi S, Pella N, Pino MS, Urbano F, Antoniotti C, Cremolini C, Corallo S, Pietrantonio F, Gelsomino F, Cascinu S, Orlandi A, Munari G, Malapelle U, Saggio S, Fontanini G, Ruggie M, Mescoli C, Lazzi S, Reggiani Bonetti L, Lanza G, Dei Tos AP, De Maglio G, Martini M, Bergamo F, Zagonel V, Loupakis F, Fassan M. **Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.** *Clinical Cancer Research.* (2019) 25(13) :3954-3961. doi: 10.1158/1078-0432.CCR-19-0311.

-
- Antoniotti C, Pietrantonio F, Corallo S, de Braud F, Falcone A, Cremolini C. **Circulating tumor DNA analysis in colorectal cancer: From dreams to reality.** *JCO Precision Oncology* (2019) 3: 1-14

-
- Moretto R, Morano F, Ongaro E, Rossini D, Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F, Cortiula F, Nichetti F, Borelli B, Zucchelli G, Boccaccino A, Masi G, de Braud F, Falcone A, Cremolini C. **Lack of benefit from anti-EGFR treatment in RAS and BRAF wild-type metastatic colorectal cancer with**

mucinous histology or mucinous component. *Clinical Colorectal Cancer* (2019) doi: <https://doi.org/10.1016/j.clcc.2019.02.007>

-

- Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C and Pietrantonio F. **Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.** *Scientific Reports* (2019) 9:2858

-

- Schwartz S, Szeto C, Tian T, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fuca` G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. **Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT.** *European Journal of Cancer* 107 (2019): 164e174

-

- Pietrantonio F, Alessi A, Raimondi A, Mennitto A, Belfiore A, Padovano B, Cotsoglou C, de Braud F, Morano F, Perrone F, Nichetti F, Fucà G, Randon G, Coppa JC, Mariani L, Di Bartolomeo M, Antista M, Vaiani M, Milione M, Prisciandaro M, Droz-Dit Busset M, Lo Vullo S, Corallo S, Lazzati S, Mazzaferro V. **Perioperative bevacizumab-based triplet chemotherapy in patients with potentially resectable colorectal cancer liver metastases.** *Clinical Colorectal Cancer* (2019) 18 (1):34–43.

-

- Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. **Temozolomide And Irinotecan (Temiri Regimen) As Salvage Treatment Of Irinotecan-Sensitive Advanced Colorectal Cancer Patients Bearing Mgmt Methylation** *Ann Oncol* (2018) 29(8):1800-1806. doi: 10.1093/annonc/mdy197

-

- Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M. et al. **Biomarkers Of Primary Resistance To Trastuzumab In Her2-Positive Metastatic Gastric Cancer Patients: The Amnesia Case-Control Study.** *Clin Cancer Res* (2018) 24(5):1082-1089 .

-

- Corallo S; D'Argento E; Strippoli A, Basso M, Monterisi S, Rossi S, Cassano A, Barone CM. **Treatment options for EGFR T790M-negative egfr tyrosine kinase inhibitor-resistant non-small cell lung cancer;** *Targeted Oncology* (2017) 12:153-161.

I authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003, n. 196 "Code regarding the

protection of personal data".

The undersigned declares that what is reported in this Curriculum Vitae corresponds to reality.

Milan, 15 JUL 2024

Dott. Salvatore Corallo